The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
Trastuzumab is the first antibody that has shown clinical activity in patients with HER-2-positive breast cancer. The mechanism of action is not fully understood; however, antibody-derived cellular cytotoxicity (ADCC) is considered to explain important peculiarities of its clinical activity such as treatment beyond progression. Based on early pre-clinical data, trastuzumab was used beyond progression...
Interleukin 1 (IL-1) and IL-10 are critically involved in tumorigenesis. We investigated polymorphisms of IL-1 and IL-10 genes in patients with ovarian cancer (OC).In a prospective, case–control study 147 patients with OC and 129 patients without history of any malignancy (CG) were genotyped for IL-1 gene (IL-1α −889 T/C and IL-1β −511 C/T) and IL-10 gene (IL-10 −1082 G/A, −819 C/T and −592 C/A) using...
Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.